C-Reactive Protein and Covid-19 Severity : A Systematic Review
Copyright © 2021 by West African Journal of Medicine..
BACKGROUND: COVID-19 clinical course has been quite unpredictable and efforts have been made to identify reliable markers that will help in early disease progression, prognosis and severity detection. Objective: This study thus aimed to provide evidence that will guide clinical management by reviewing studies that assessed CRP concentration and COVID-19 severity/outcome.
METHODS: Three electronic databases, PubMed/Medline, Google Scholar, and JSTOR were searched to identify studies available online as at 1st September 2020 which assessed COVID-19 clinical outcome and CRP concentration. The search strategy involved words combination like "C-reactive protein" OR "inflammatory markers" OR "acute phase reactants" and "coronavirus 2019" OR ''COVID-19" OR "2019-nCoV" OR "SARS-CoV-2".
RESULTS: Sixty-one articles were systematically reviewed out of 812 studies identified after duplicates were removed. The 61 studies comprised 13,891 COVID-19 patients made of 7,840 (56.4%) males and 6,051 (43.6%) females. All the papers revised were observational studies except one case-control and they cut across fifteen countries. The result of the review demonstrated that the severe cases had higher levels of C - reactive protein when compared to the mild cases in all the studies (100%). The increase in C-reactive protein was statistically significant in 78.7% of the cases.
CONCLUSION: High levels of CRP are associated with COVID-19 severity.
Highlights: Severe cases of COVID-19 is characterized with higher CRP levels. COVID-19 cases should be screened regularly for CRP to monitor severity.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:Vol. 38 |
|---|---|
| Enthalten in: |
West African journal of medicine - Vol. 38(2021), 10 vom: 29. Okt., Seite 1011-1023 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ikeagwulonu, R C [VerfasserIn] |
|---|
| Themen: |
9007-41-4 |
|---|
| Anmerkungen: |
Date Completed 06.12.2021 Date Revised 31.05.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM333936221 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333936221 | ||
| 003 | DE-627 | ||
| 005 | 20231225222656.0 | ||
| 007 | tu | ||
| 008 | 231225s2021 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM333936221 | ||
| 035 | |a (NLM)34856793 | ||
| 035 | |a (PII)West Afr J Med. | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ikeagwulonu, R C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a C-Reactive Protein and Covid-19 Severity |b A Systematic Review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2021 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 by West African Journal of Medicine. | ||
| 520 | |a BACKGROUND: COVID-19 clinical course has been quite unpredictable and efforts have been made to identify reliable markers that will help in early disease progression, prognosis and severity detection. Objective: This study thus aimed to provide evidence that will guide clinical management by reviewing studies that assessed CRP concentration and COVID-19 severity/outcome | ||
| 520 | |a METHODS: Three electronic databases, PubMed/Medline, Google Scholar, and JSTOR were searched to identify studies available online as at 1st September 2020 which assessed COVID-19 clinical outcome and CRP concentration. The search strategy involved words combination like "C-reactive protein" OR "inflammatory markers" OR "acute phase reactants" and "coronavirus 2019" OR ''COVID-19" OR "2019-nCoV" OR "SARS-CoV-2" | ||
| 520 | |a RESULTS: Sixty-one articles were systematically reviewed out of 812 studies identified after duplicates were removed. The 61 studies comprised 13,891 COVID-19 patients made of 7,840 (56.4%) males and 6,051 (43.6%) females. All the papers revised were observational studies except one case-control and they cut across fifteen countries. The result of the review demonstrated that the severe cases had higher levels of C - reactive protein when compared to the mild cases in all the studies (100%). The increase in C-reactive protein was statistically significant in 78.7% of the cases | ||
| 520 | |a CONCLUSION: High levels of CRP are associated with COVID-19 severity | ||
| 520 | |a Highlights: Severe cases of COVID-19 is characterized with higher CRP levels. COVID-19 cases should be screened regularly for CRP to monitor severity | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a C-reactive protein | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-COV-2 andCoronavirus | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a CRP protein, human |2 NLM | |
| 650 | 7 | |a Receptors, Immunologic |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 700 | 1 | |a Ugwu, N I |e verfasserin |4 aut | |
| 700 | 1 | |a Ezeonu, C T |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeagwulonu, Z C |e verfasserin |4 aut | |
| 700 | 1 | |a Uro-Chukwu, H C |e verfasserin |4 aut | |
| 700 | 1 | |a Asiegbu, U V |e verfasserin |4 aut | |
| 700 | 1 | |a Obu, D C |e verfasserin |4 aut | |
| 700 | 1 | |a Briggs, D C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t West African journal of medicine |d 1993 |g Vol. 38(2021), 10 vom: 29. Okt., Seite 1011-1023 |w (DE-627)NLM012653942 |x 0189-160X |7 nnns |
| 773 | 1 | 8 | |g volume:Vol. 38 |g year:2021 |g number:10 |g day:29 |g month:10 |g pages:1011-1023 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d Vol. 38 |j 2021 |e 10 |b 29 |c 10 |h 1011-1023 | ||